- Home
- ESLA vs TURN Comparison
ESLA vs TURN Comparison
Compare ESLA & TURN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESLA
- TURN
- Stock Information
- Founded
- ESLA 2021
- TURN 1981
- Country
- ESLA United States
- TURN United States
- Employees
- ESLA N/A
- TURN N/A
- Industry
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- TURN Finance/Investors Services
- Sector
- ESLA Health Care
- TURN Finance
- Exchange
- ESLA Nasdaq
- TURN Nasdaq
- Market Cap
- ESLA 41.6M
- TURN 35.4M
- IPO Year
- ESLA N/A
- TURN N/A
- Fundamental
- Price
- ESLA $1.07
- TURN $3.67
- Analyst Decision
- ESLA
- TURN
- Analyst Count
- ESLA 0
- TURN 0
- Target Price
- ESLA N/A
- TURN N/A
- AVG Volume (30 Days)
- ESLA 23.1K
- TURN 32.1K
- Earning Date
- ESLA 02-12-2025
- TURN 02-18-2025
- Dividend Yield
- ESLA N/A
- TURN N/A
- EPS Growth
- ESLA N/A
- TURN N/A
- EPS
- ESLA N/A
- TURN N/A
- Revenue
- ESLA N/A
- TURN $129,297.00
- Revenue This Year
- ESLA N/A
- TURN N/A
- Revenue Next Year
- ESLA N/A
- TURN N/A
- P/E Ratio
- ESLA N/A
- TURN N/A
- Revenue Growth
- ESLA N/A
- TURN 6.32
- 52 Week Low
- ESLA $0.63
- TURN $3.12
- 52 Week High
- ESLA $3.23
- TURN $4.47
- Technical
- Relative Strength Index (RSI)
- ESLA 44.96
- TURN 54.33
- Support Level
- ESLA $1.02
- TURN $3.57
- Resistance Level
- ESLA $1.22
- TURN $3.67
- Average True Range (ATR)
- ESLA 0.17
- TURN 0.13
- MACD
- ESLA -0.02
- TURN -0.01
- Stochastic Oscillator
- ESLA 16.67
- TURN 77.42
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
About TURN 180 Degree Capital Corp.
180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.